Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | SVP, Research & CSO | March 21, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date March 21, 2024 · Filed May 14, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.21 · Expires 2034-03-21 | Direct | 1,341 |
Reported balance
After 2024-03-21 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-03-21 · Grant · Acquired 1,341 · Balance 1,341 F1: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4. F2: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4.
F2: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2024 Filed May 14, 2024 16:36 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,341 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001062993-24-010189 · form4a.xml · derivative · entry 1 Smith Ernest S. · CIK 0001747769 · SVP, Research & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,341 Underlying: Common Stock · 1,341 shares Expires 2034-03-21 F1 · derivative.exercise_price: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4. F1 · date: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4. F2 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 16:32 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,341 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001062993-24-006959 · form4.xml · derivative · entry 9 Smith Ernest S. · CIK 0001747769 · SVP, Research & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,341 Underlying: Common Stock · 1,341 shares Expires 2034-03-20 F5 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 20, 2024 grant date. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 16:33 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001062993-23-008322 · form4.xml · derivative · entry 8 Smith Ernest S. · CIK 0001747769 · SVP, Research & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-03-30 F5 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 16:37 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001062993-22-009451 · form4.xml · derivative · entry 7 Smith Ernest S. · CIK 0001747769 · SVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-04-01 F5 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date. Read SEC document |
| April 02, 2021 Filed Apr 2, 2021 16:25 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0000891839-21-000098 · edgar.xml · derivative · entry 6 Smith Ernest S. · CIK 0001747769 · SVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-04-02 F4 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 16:24 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0000891839-20-000052 · edgar.xml · derivative · entry 5 Smith Ernest S. · CIK 0001747769 · SVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-02-24 F4 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 17:04 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0000891839-19-000049 · edgar.xml · derivative · entry 4 Smith Ernest S. · CIK 0001747769 · SVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-03-14 F3 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.